ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 563,02
-0,91%
Dow Jones
40 697,88
1,21%
DAX
18 481,42
-0,64%
Brent Oil
83,10
-1,47%
Bitcoin
63 223,58
-2,51%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Teva Pharmaceutical Industries Ltd (TEVA)

  7. Teva Pharmaceutical Industries Ltd (TEVA) Actualités

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:TEVA
DateHeureSourceTitreSymboleSociété
06/07/201718h15PR Newswire (US)German Federal Joint Committee (G-BA) Confirms Evidence for Additional Benefit for CINQAERO® (reslizumab) in Severe Asthma P...NYSE:TEVATeva Pharmaceutical Industries Ltd
01/07/201700h59Dow Jones NewsADRs End HigherNYSE:TEVATeva Pharmaceutical Industries Ltd
30/06/201723h05Dow Jones NewsOklahoma Sues Opioid Painkiller Makers -- 2nd UpdateNYSE:TEVATeva Pharmaceutical Industries Ltd
30/06/201722h40Dow Jones NewsOklahoma Sues Opioid Painkiller Makers -- UpdateNYSE:TEVATeva Pharmaceutical Industries Ltd
30/06/201721h19Dow Jones NewsOklahoma Sues Opioid Painkiller MakersNYSE:TEVATeva Pharmaceutical Industries Ltd
29/06/201714h58Edgar (US Regulatory)Report of Foreign Issuer (6-k)NYSE:TEVATeva Pharmaceutical Industries Ltd
29/06/201714h30Business WireCelltrion & Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Rituxan® (rituximab)NYSE:TEVATeva Pharmaceutical Industries Ltd
29/06/201714h00Business WireTeva Announces Publication of AIM-TD Study Results in The Lancet Psychiatry for the Investigational Use of Deutetrabenazine i...NYSE:TEVATeva Pharmaceutical Industries Ltd
27/06/201714h15GlobeNewswire Inc.Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primar...NYSE:TEVATeva Pharmaceutical Industries Ltd
27/06/201714h15Business WireTeva & Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary ...NYSE:TEVATeva Pharmaceutical Industries Ltd
22/06/201723h44Dow Jones NewsADRs End Higher; Pharmaceuticals Trade ActivelyNYSE:TEVATeva Pharmaceutical Industries Ltd
13/06/201709h03Dow Jones NewsNassau Sues Drugmakers Over Opioids -- WSJNYSE:TEVATeva Pharmaceutical Industries Ltd
13/06/201701h48Dow Jones NewsNassau County Sues Drugmakers Over Opioid EpidemicNYSE:TEVATeva Pharmaceutical Industries Ltd
12/06/201722h48Dow Jones NewsNassau County Sues Drug Makers Over Opioid EpidemicNYSE:TEVATeva Pharmaceutical Industries Ltd
12/06/201721h16Business WireTeva Announces Launch of Generic Zetia® in the United StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
09/06/201714h53Business WireTeva Announces Exclusive Launch of Generic Pataday® in the United StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
07/06/201714h00Business WireTeva's Fremanezumab Meets all Primary & Secondary Endpoints Across Both Monthly & Quarterly Dosing Regimens in Phase III Stud...NYSE:TEVATeva Pharmaceutical Industries Ltd
06/06/201714h00Business WireTeva to Present at the Jefferies 2017 Global Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
01/06/201714h00Business WireTeva to Present Data from 18 Abstracts in Tardive Dyskinesia & Huntington Disease at the 21st International Congress of Parki...NYSE:TEVATeva Pharmaceutical Industries Ltd
01/06/201709h02Dow Jones NewsOpioid Makers Sued for Stoking Addiction -- WSJNYSE:TEVATeva Pharmaceutical Industries Ltd
01/06/201703h58Dow Jones NewsOhio Sues Five Drug Firms, Saying They Fueled Opioid Crisis -- 2nd UpdateNYSE:TEVATeva Pharmaceutical Industries Ltd
31/05/201723h16Edgar (US Regulatory)Specialized Disclosure Report (sd)NYSE:TEVATeva Pharmaceutical Industries Ltd
31/05/201721h12Dow Jones NewsOhio Sues Five Drug Firms, Saying They Fueled Opioid Crisis -- UpdateNYSE:TEVATeva Pharmaceutical Industries Ltd
31/05/201714h22Business WireTeva Announces Positive Results for Phase III Study of Fremanezumab for the Prevention of Chronic MigraineNYSE:TEVATeva Pharmaceutical Industries Ltd
17/05/201715h00Business WireTeva Showcases Asthma Research at the 2017 American Thoracic Society (ATS) International ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
17/05/201714h00Business WireTeva to Present Data for Deutetrabenazine in Tardive Dyskinesia at the American Psychiatric Association 2017 Annual MeetingNYSE:TEVATeva Pharmaceutical Industries Ltd
15/05/201719h20Business WireTeva Announces Launch of Generic Glumetza® in the United StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
15/05/201714h00Business WireOtsuka and Teva Sign Licensing Agreement for Japan on Prophylactic Migraine Drug Candidate Fremanezumab (TEV-48125)NYSE:TEVATeva Pharmaceutical Industries Ltd
11/05/201713h00Business WireTeva Reports First Quarter 2017 Financial ResultsNYSE:TEVATeva Pharmaceutical Industries Ltd
09/05/201717h52Dow Jones NewsThin Is In as Allergan Dodges Generics Bullet -- Heard on the StreetNYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA

Dernières Valeurs Consultées

LSE
0QJ4
Napatech A/s
NASDAQ
SNDL
Sundial Growers
USOTC
VYCO
Vycor Medical (QB)
LSE
ABAL
Abal
AQSE
NANO.GB
Nanoco
NASDAQ
SRRK
Scholar Rock
TSX
CUF.UN
Cominar Real Estate Inve...
NASDAQ
CHCO
City
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés